8-K
filed May 8, 2025, 7:59 PM ET
ticker LSTA
CIK 0000320017
earnings
confidence high
sentiment neutral
materiality 0.60
Lisata Q1 net loss $4.7M; cash $25.8M; ASCEND Cohort B oral at ESMO-GI Jul 2025
LISATA THERAPEUTICS, INC.
2025-Q1 EPS
reported -$0.55
vs consensus -$0.54
▼ miss
(-1.7%)
- Net loss $4.7M for Q1 2025, vs $5.4M in Q1 2024; operating expenses down 11% to $5.8M.
- Cash, equivalents, and marketable securities $25.8M as of Mar 31, 2025; runway into Q3 2026.
- Cohort B of ASCEND trial (mPDAC) accepted for oral presentation at ESMO-GI July 2025; final analysis pending.
- BOLSTER trial in first-line cholangiocarcinoma fully enrolled; topline data anticipated mid-2025.
- Qilu's Phase 2 certepetide trial in China complete; Phase 3 start triggers $10M milestone payment.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0000320017-25-000028
- form_type
- 8-K
- ticker
- LSTA
- cik
- 0000320017
- company_name
- LISATA THERAPEUTICS, INC.
- filed_at
- 2025-05-08T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:50.931740+00:00
- generated_at
- 2026-05-22T05:53:45.650375+00:00
- sec_items
- ["2.02", "7.01", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.6
- calibrated_materiality_score
- 0.6
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0000320017-25-000028
- json_url
- https://secwatch.observer/filing/0000320017-25-000028.json
- markdown_url
- https://secwatch.observer/filing/0000320017-25-000028.md
- text_url
- https://secwatch.observer/filing/0000320017-25-000028.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/0000320017-25-000028-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/clbs-20250508.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
KSS
Kohl's Q1 net loss $14M; comparable sales down 1.1% YoY; affirms FY outlook
KOHLS Corp
May 28, 2026, 7:00 AM ET
earnings
Items 2.02, 7.01, 8.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BAH
Booz Allen reports Q4 revenue down 6.4% to $2.78B; adjusted EPS up 10.6% to $1.78
Booz Allen Hamilton Holding Corp
May 22, 2026, 6:49 AM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DEERE JOHN CAPITAL CORP
John Deere Capital Q2 net income up 22% to $151M, portfolio down 3%
DEERE JOHN CAPITAL CORP
May 21, 2026, 6:17 AM ET
earnings
Items 2.02, 7.01, 8.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DE
Deere reports Q2 FY2026 results; press release omitted from filing text
DEERE & CO
May 21, 2026, 6:00 AM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
FJET
Starfighters Space Q1 net loss widens to $4.27M on $0 revenue; cash drops to $1.40M
Starfighters Space, Inc.
May 20, 2026, 9:55 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
KEY
KeyCorp reports 1Q26 diluted EPS $0.44, NII up 11% YoY; targets 3.25%+ NIM by 4Q27
KEYCORP /NEW/
May 29, 2026, 5:12 PM ET
earnings
Items 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.